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ABSTRACT: Interferons are commonly utilized in the treatment of chronic hepatitis
B virus (HBV) infection but are not effective for all patients. A deep understanding of
the limitations of interferon treatment requires delineation of its activity at multiple
“omic” levels. While myriad studies have characterized the transcriptomic effects of
interferon treatment, surprisingly, few have examined interferon-induced effects at the
proteomic level. To remedy this paucity, we stimulated HepG2 cells with both IFN-α
and IFN-λ and performed proteomic analysis versus unstimulated cells. Alongside, we
examined the effects of HBV transfection in the same cell line, reasoning that parallel
IFN and HBV analysis might allow determination of cases where HBV transfection
counters the effects of interferons. More than 6000 proteins were identified, with
multiple replicates allowing for differential expression analysis at high confidence.
Drawing on a compendium of transcriptomic data, as well as proteomic half-life data,
we suggest means by which transcriptomic results diverge from our proteomic results.
We also invoke a recent multiomic study of HBV-related hepatocarcinoma (HCC),
showing that despite HBV’s role in initiating HCC, the regulated proteomic landscapes of HBV transfection and HCC do not
strongly align. Special focus is applied to the proteasome, with numerous components divergently altered under IFN and HBV-
transfection conditions. We also examine alterations of other protein groups relevant to HLA complex peptide display, unveiling
intriguing alterations in a number of ubiquitin ligases. Finally, we invoke genome-scale metabolic modeling to predict relevant
alterations to the metabolic landscape under experimental conditions. Our data should be useful as a resource for interferon and
HBV researchers.
■ INTRODUCTION
Type-I interferon (IFN-I) stimulus is known to generate a
stereotyped response.1 The response, as defined by regulation of
key proteins or transcripts, does not seem limited to cell type2
and can be initiated by the presence of viruses, bacteria,
parasites, and any number of purified components thereof
[dsRNA, lipopolysaccharide (LPS), etc.].3,4 The use of type-I
IFNs as a treatment against a wide range of infectious conditions
has been shown efficacious.5 Additionally, IFN-I treatment has
shown benefits in conditions ranging from multiple sclerosis6 to
cancer7 because of immunomodulatory and/or proapoptotic
effects.
An extraordinary number of transcriptomic studies have
measured differential effects of IFN-I against controls in a wide
variety of cell types and organisms; we estimate that the GEO
database lists approximately 100 such studies in human cells
alone.8 Given well-known disparities between mRNA and
protein levels, it is then surprising to find that high-resolution
proteomic studies of the IFN response are lacking. Searching the
literature, a 2017 work in which IFN-α (a type-I interferon) and
IFN-γ (type II) were applied to MRC-5 lung fibroblast cells
would be the deepest study to date, emphasizing time course
effects and differential IFN-α/IFN-γ results.9 Another deep
proteomic analysis of IFN-γ effects on mesenchymal stromal/
stem cells10 has been conducted, but such results would not be
expected to be good proxies for IFN-I effects, given the
differences in pathways that are triggered upon type I or II
stimulation.11 We previously conducted a high-depth analysis of
IFN type I and III effects on a human hepatoblastoma cell line
transfected with HBV (HepG2.2.15), with the aim of testing
potential therapeutic effects;12 however, this setting would not
be ideal for the study of authentic IFN effects, as viral versus IFN
stimulation of cells might well overlap upon analysis of altered
protein expression.
In this study, we use modern technology to resolve the IFN-I-
stimulated proteome in the HepG2 human hepatoblastoma cell
line. We also examine the effects of IFN-III stimulation, which is
thought to stimulate a response similar to that of IFN-I but may
offer reduced side-effects by virtue of its specificity for epithelial
cells.13 A comparison of HBV-transfected versus native HepG2
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cells is also conducted, possibly allowing discrimination between
a state induced by chronic viral infection and a state induced by
IFN treatment. With the aim of providing a comprehensive
analysis, we also incorporate data from our previous HBV-
focused proteomic work.12 In all cases, multiple biological
replicates are performed which, combined with modern
methods, allow discernment of considerably more protein
identifications than previous IFN-related studies. Our data are
offered as a resource for further investigations at http://sysbio.
chula.ac.th/IFN_HepG2_Proteomics/.
■ RESULTS AND DISCUSSION
Data Overview. Prior to dissecting our data, we should
point out a limitation of a portion of our work. In the case where
HBV-transfected (HepG2.2.15) cells were compared against
HepG2, a control vector was not transfected into HepG2. To
retain the HBV-expression plasmid, cells were treated with the
antibiotic Geneticin. This approach mirrors other studies in
which HepG2.2.15 has been compared with HepG2.14−21
Nevertheless, the lack of a control vector and Geneticin within
HepG2 cannot be excluded as a cause of differential results when
comparing HepG2.2.15 cells against HepG2. Readers should
also note that all differential proteomic results, unless otherwise
noted, were acquired at 24 h post-treatment; longer or shorter
treatment periods could result in significantly different profiles.
Finally, these results were established in vitro; systemic delivery
of IFN or infection with HBV in an appropriate in vivo model
may also generate different results.
In order to dissect the IFN-response in HepG2 cells and to
compare the IFN-response to an HBV-transfection induced
state, we performed two experiments, with five replicates in
each: HepG2 cells with/without IFN-I or IFN-III stimulation
(IFN-α2 or IFN-λ3) and a comparison of HepG2 cells versus
HepG2.2.15 cells; in addition, we also included our previously
published work:12 HepG2.2.15 cells with/without IFN-I or
IFN-III stimulation, into our bioinformatic analysis (Figure 1).
Figure 2a,b attests to consistency between replicates in our
two new proteomic studies, with proteins found in all five
replicates being the dominant intersection. In all, we confidently
identified a total of 6003 proteins in this study, of which 2830
were differentially regulated under at least one condition and
5708 proteins appeared under at least two conditions (P < 0.05,
Student’s t-test, Figure 2c). Including results from our previous
study of the effects of interferon treatment on HBV-transfected
cells, we conducted PCA analysis on the differential protein
expression data from the resulting 25 mass spectrometry (MS)
samples (Figure 2d) from three dimethyl labeling experiments
(HepG2.2.15 vs HepG2, HepG2 with IFN-α/λ vs control, and
HepG2.2.15 with IFN-α/λ vs control). As expected, these three
experiments are apparent in the distinct locations of ellipses in
the figure. Clusters include the HBV-transfection group more
tightly, possibly due to the aforementioned broad effects of
transfection.
The HepG2-IFN/HepG2 and HepG2.2.15/HepG2 compar-
isons are depicted as volcano plots (Figure 3). A total of 401
proteins were differentially expressed on IFN-I stimulation (260
up and 141 down), 711 on IFN-III stimulation (467 up and 244
Figure 1. Schematic overview of the experimental design and workflow.
ACS Omega http://pubs.acs.org/journal/acsodf Article
https://dx.doi.org/10.1021/acsomega.0c01865
ACS Omega 2020, 5, 16796−16810
16797
down), and 2434 (954 up and 1480 down) in the HepG2.2.15
cells versus HepG2 comparison; 1689 proteins were not
differentially expressed under any of the three conditions.
Thus, in the IFN-I/III conditions, 12 and 7% of all proteins
showed altered expression. Note that the MTT assays in our
previous work12 were used to establish IFN treatment
concentrations that were not detrimental to cell survival, so
the above-mentioned differential results cannot be interpreted
as alterations that would be expected because of cell death. Not
surprisingly, proteins identified as upregulated/downregulated
under IFN-I treatment strongly overlapped with those
upregulated/downregulated under IFN-III treatment (P =
10−107/P = 10−46). As expected, the HBV-C protein was
expressed only in the HBV-transfection condition. Several
features of these plots should be pointed out. First, while IFN-
treatment clearly elicits a powerful and stereotyped effect (see
below), the extent to which HBV-transfection alters protein
expression was surprising; 59% of all detected proteins were
differentially expressed in the HepG2.2.15/HepG2 comparison,
a figure not approached in either IFN treatment. Second, while it
has been claimed, based on transcriptomics, that no interferon
response is detectable upon HBV infection,22,23 this effect is
obvious at the proteomic level in the comparison of HepG2.2.15
to HepG2, with innate immune components such as IFIT1 and
IFIT3 upregulated with high significance.
Proteomics Versus Transcriptomics. The correlations
between differential transcriptomic and proteomic results are
the subject of intense, ongoing debate.24,25 We constructed lists
of the most commonly up- and downregulated transcripts upon
IFN-I or III stimulation using 18 studies (Table S1). For
inclusion in the list of upregulated transcripts, the transcript was
required to appear at least four times and for downregulated
transcripts, three times. No more than 200 transcripts were
entered in these lists. The stereotypical nature of the IFN
response is seen in the observation that three known interferon-
inducible transcripts (IFIT1, USP18, and RSAD2)26−28 were
shown to be upregulated in 16 of these studies; at the same time,
only one transcript was downregulated more than 6 times in
these studies (CERK). Comparing our HepG2 proteomic
results against these transcriptomic lists, a strong overlap is seen
in the case of upregulation (P = 10−17 on IFN-I treatment, 10−9
on IFN-III treatment, Fisher’s exact test) (Figure 4b). Similar
results were seen in HepG2.2.15 (P = 10−15 on IFN-I treatment,
10−13 on IFN-III treatment). Interestingly, the overlaps were
Figure 2. Two dimethyl-labeling experiments consisting of 5 reps (samples) each were performed. Five-way Venn diagrams depict proteins identified
in each sample. Only proteins found in at least 3 reps are counted. (a) Counts of proteins identified in the HepG2 control, IFN-α2-treated HepG2, and
IFN-λ3-treated HepG2 comparisons are shown. (b) Counts of proteins in the HepG2.2.15 vs HepG2 control comparison are shown. Note that the
predominant grouping is the case where a protein can be found in all five samples. (c) Venn diagram shows conditions under which proteins could be
identified in both treatment and control conditions (note that the IFN-λ IDs are subsumed by the IFN-α IDs). (d) PCA diagram shows clustering of 25
samples (five experimental conditions and five repetitions).
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insignificant when downregulated transcripts were compared
against downregulated HepG2 or HepG2.2.15 proteins. To
further dissect transcript/protein relations, we conducted
Pearson correlation tests using differential data from our own
proteomic studies and 15 of the above-mentioned tran-
scriptomic studies (in three cases, complete transcriptomic
datasets were not available) (Figure 4a). In 14 of these studies,
positive proteomic/transcriptomic correlations are seen, with P
< 10−15 in 5 cases. Despite these correlations, the near-flat slope
of these plots illustrates that under IFN-stimulation, proteins
have a considerably wider dynamic range than transcripts. Figure
S1 reinforces the aforementioned observation that proteome/
transcriptome correlations are strongest in the case of
upregulation; here, when downregulated proteins were removed
from the underlying dataset, R values and slopes clearly
increased, while P-values uniformly decreased.
A hint as to the cause of the disparity between downregulated
transcripts and proteins may be seen in a comparison of our
IFN-I/III treatment results against two proteomic studies that
sought to determine protein half-lives.24,29 We averaged IFN-I
and IFN-III fold changes, selected only proteins that showed a
significant change in at least one of these two IFN treatments,
and compared these results against proteins shown to have long
half-lives inmouse fibroblasts24 using Fisher’s exact test, defining
24 h (the duration of IFN exposure in our work) as the cutoff
between “short-lived” and “long-lived” proteins. Here, only the
overlap of proteins downregulated upon IFN treatment and
proteins with long half-lives reached significance (P = 0.01).
Changing the threshold of “long-lived” to be 100 h or more
(approximately 25% of all proteins) resulted in P = 1.3 × 10−6.
Performing the same exercise with Mathieson’s mouse
hepatocyte data,29 we derive P = 0.001 when examining IFN-
downregulated proteins against long-lived proteins. Again,
significance increased when proteins with half-lives greater
than 100 h (approximately 33% of all proteins) were intersected
with proteins downregulated on IFN treatment: P = 8 × 10−6. It
is possible, then, that IFN treatment has a general effect of
decreasing proteins with long half-lives, suggesting increased
degradation versus decreased production. A relative lack of
RNA/protein correlation upon downregulation versus upregu-
lation has been previously noted, suggesting a prominent role for
protein degradation processes in widening the RNA/protein
gap.30−32
Another potentially insightful exercise is to search for cases
where the proteomic and transcriptomic data are in opposition.
We identified only two cases, both involving proteins we found
to be upregulated upon IFN-III treatment but typically
downregulated at the transcriptomic level: RRM2 and BUB1B
(no cases of protein downregulation/transcript upregulation
were found). Interestingly, both are involved in the cell cycle, are
highly expressed in numerous cancers, and are predictive of poor
cancer outcomes.33−36 Such results point out how, in some
cases, transcriptomics fails to predict the direction of protein
differential regulation. To seek out overlooked proteins that may
Figure 3. Volcanos. Volcano plots display the distribution of identified
proteins according to significance and fold-change in (a) HBV-
transfection condition, (b) IFN-III stimulation condition, and (c) IFN-
I stimulation condition. Individual proteins exceeding minimum
significance and fold-change thresholds are noted, with colors
Figure 3. continued
indicating membership in three prominent gene ontology groups.
These groups were chosen such that genes in one group were not found
in the other two groups. Proteins that exceeded fold-change and
significance thresholds are labeled, with colors indicating proteins that
fall into broad GO enrichment groups of interest. In the case of (a), the
presence of the HBV core protein is noted, represented by “C”.
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play prominent roles in the interferon response without being
upregulated at the transcript level, we scanned our data for
proteins that were highly significantly upregulated (P < 0.001) in
both IFN-α2 and IFN-λ3 treatment conditions yet did not
appear on our list of canonical IFN-upregulated transcripts in
IFN treatments ranging from 6 h to 8 days. Four such proteins
were found: CHDH, SRBD1, SLC25A31, and SFXN4. While
the small size of this group makes enrichment analysis
unprofitable, it is interesting that three of the four proteins are
primarily mitochondrial (SRBD1 is not), hinting that a subset of
mitochondrial proteins are stabilized upon IFN-α/λ treatment,
or their transcripts are more efficiently translated, possibly
hinting at an overlooked response to these IFNs.
Deconvoluting HBV-Transfection and IFN-Induced
Effects. To further elucidate the proteome-level interferon
response in HepG2 cells, we combined our previously generated
data regarding the effect of IFN-treatment on HBV-transfected
cells with our current data. The result is shown as a heatmap in
Figure 5, with five clusters of expression patterns emerging from
the five conditions. The first cluster can easily be described as
“antiviral” in nature, with significant upregulation of interferon-
response components under all conditions. The second cluster
shows proteins that are strongly downregulated upon HBV-
transfection but upregulated on IFN-treatment; we would term
this cluster “IFN reverses the downregulation caused by HBV
transfection.” Of the enrichment groups that appear in the
figure, we would question the usefulness of terms such as
“acetylation” given that PTMs occur at the peptide level, with
modifications possibly being up- and downregulated on a single
protein. Nevertheless, it is worth noting that proteins in this
cluster have been described in individual studies as targets of
PARP-ylation (log(P) = −3.3),37 sumoylation (−1.8),38 and
phosphorylation (−1.7),39 in addition to acetylation. The third
cluster is the converse of the second: “IFN diminishes the
upregulation caused by HBV transfection.” The fourth cluster
shows proteins that are strongly downregulated upon IFN
stimulation but countered by HBV transfection; “IFN down-
regulation reversed by HBV transfection.” Here, enrichment is
seen for proteasome core components, again suggesting that
HBV actively alters the abundance of these components. The
final group, cluster five, is rather perplexing. Here, proteins that
are upregulated upon IFN treatment are downregulated upon
HBV transfection, with IFN appearing to enhance, not reverse,
this downregulation in HBV-transfected cells: “IFN enhances
the downregulation caused by HBV transfection.” We note the
presence of TBK1 in this group, a kinase that is targeted by
numerous viruses in order to suppress the interferon
response.40−42 One of the HBV proteins, HBx, has been
shown to interact with TBK1, thus altering IFN signaling.43 One
might speculate that HBV somehow redirects the activity of an
interferon-stimulated kinase (such as TBK1) or ubiquitylase to
target a subset of interferon-stimulated proteins, giving rise to
the aforementioned perplexing behavior.
Relevance to Immunoprocessing. Proteasome compo-
nents were prominent in the volcano plots showing IFN-
stimulated alterations, prompting further examination of this
structure. Here, differences between the HepG2-IFN/HepG2
(IFN) conditions versus the HepG2.2.15/HepG2 (HBV-
transfection) condition were clear. In the HBV-transfection
condition, all proteasome components failed to exceed 2-fold
up-/downregulation. Meanwhile, four proteasome components,
all downregulated, exceeded this threshold upon IFN-
stimulation (Figure 6, proteasome table). These large alterations
all involved the core alpha and beta components of the
Figure 4. Proteomics vs transcriptomics. (a) Pearson correlation analysis of 15 transcriptomic studies in which IFN-λ3 and IFN-α2 were applied to
various cell types vs our own IFN-treatment-based proteomic results. Axes depict log 2 fold alterations. Violin plot (lower right hand corner) depicts
the distribution of R-values generated in these 15 tests. See Figure S1 for tests in which downregulated or upregulated proteins were excluded from the
analysis; here, it becomes apparent that protein/transcript correlations are much stronger when examining upregulation vs downregulation. (b) Venn
diagram displays intersection of transcripts canonically upregulated on IFN treatment against proteins upregulated on either IFN-α2 or IFN-λ3
treatment.
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constitutive proteasome. The downregulated PSMB5 protein is
one of the three core components replaced in immunoprotea-
some formation, while PSME1 and PSME2, accessory
components unique to the immunoproteasome, were upregu-
lated upon IFN stimulation. We note that significant down-
regulation of the four aforementioned core components without
concomitant alterations in “accessory” components has also
been identified via MS in lymphocytes upon IL-2 and IL-15
stimulation.44 As with IFN-α/λ, these cytokines are expected to
act on the JAK/STAT signaling pathway. Meanwhile, differ-
ential upregulation of immunoproteasome components (vs the
constitutive proteasome) is seen at the transcript level on IFN-α
treatment45 and extended (24 h vs 4) IFN-λ treatment46 in
human liver culture.
Given the alterations of the proteasome upon IFN treatment,
uncovered despite an absence of strong gene-enrichment
statistics, we further examined our data against protein groups
that are upstream and downstream of proteasome processing.
These groups are expected to be relevant to HLA-peptide
complex display and adaptive immune responses. A reasonable
initial hypothesis would be that HBV transfection would tend to
suppress components involved in positive regulation of this
display, while IFN treatment would enhance them. Specifically,
we examined upstream components including E3 ligases
combined with their accessory factors, as well as deubiquity-
lases.47,48 Finally, our compilation would not be complete
without a list of factors that are directly responsible for antigen
Figure 5.Heatmap shows alterations in 193 proteins under five conditions: (1) IFN-α2 and (2) IFN-λ3 stimulation of HepG2 cells; (3) IFN-α2 and
(4) IFN-λ3 stimulation of HepG2.2.15 cells; and (5)HepG2 vsHepG2.2.15 cells. For a protein’s entry into the heatmap, the following was required; of
the five log 2 ratios associated with a given protein’s differential expression changes under different experimental conditions, the smallest ratio
subtracted from the largest ratio must be greater than two. Note that expression under IFN-α2 and IFN-λ3 conditions is largely concordant. Proteins in
five expression clusters are noted in boxes, and enrichment characteristics of these groups are shown in accompanying bar graphs.
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processing and presentation, following proteasome-based
peptide processing. We dissect these groups below.
Of the groups examined, the most significant alterations
involved E3 ligases/accessories under the HBV-transfection
condition. Here, while 28 such components were down-
regulated, only 11 were upregulated (Figure 6, E3 table).
Adjusting for the fact that more proteins were significantly
downregulated than upregulated in the HBV-transfection
condition, we derive P = 0.03 via the binomial distribution.
One might hypothesize that this pattern relates to the HBV-
Figure 6. Immunoprocessing components under IFN treatment or HBV transfection. (a) Alteration of human 26S proteasome (PDB: 5L4G)
components under IFN-treatment (left) and HBV-transfection (right). The mouse immunoproteasome cap (PDB: 5MX5) is shown once, as its two
components were significantly altered under both the IFN and HBV-transfection conditions. Here, raspberry color serves only to distinguish PSME2
from PSME1. Strong red indicates significant upregulation, salmon indicates upregulation without significance, strong blue indicates significant
downregulation, and light blue indicates downregulation without significance. If either of the IFN-α2 or IFN-λ3 treatments altered protein expression
significantly, the protein in question was considered to be significantly altered. Tables showing alterations in (b) proteasome components, (c)
immunoprocessing proteins downstream of the proteasome, (d) deubiquitylases, and (e) RING ligases and their accessory proteins. Bold lettering of
fold-change data indicates significant alterations. Colors, from strong red (upregulation) to strong blue (downregulation), indicate the extent of fold
change. Candidates for proviral modulation of the proteome.
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derived IFN response; however, the effect seems to be HBV-
specific but not IFN-related, as only one ligase/accessory
protein was found to be regulated in the same direction in both
HBV-transfection and IFN conditions (FBXO22, downregu-
lated). Upregulation of ligases and their accessories did not
reach significance under IFN-treatment (P = 0.07). Deubiqui-
tylases did not evince a significant trend of alteration (Figure 6,
deubiquitylases table). The mechanism by which HBV would
perform bulk downregulation of E3 ligases and their accessory
factors is puzzling. Six factors directly involved in the HLA−
peptide complex display were significantly upregulated in the
HBV-transfection condition (P = 0.002) (Figure 6, antigen
Figure 7. (a) Metabolite and (b) subsystem directional GSA results for the five comparisons. Shown are the log 10-transformed “distinct directional”
P-values for metabolites and subsystems with P < 0.05 in at least one comparison. The log-transformed P-values are signed such that gene sets more
significantly enriched in expression decreases are negative, whereas those enriched more in expression increases are positive. (c) Metabolite and (d)
subsystem nondirectional GSA results for the five comparisons. Shown are the log 10-transformed “nondirectional” P-values for metabolites and
subsystems with P < 0.05 in at least one comparison.
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processing table). Here, however, IFN induction could be
involved, as four of these factors were also upregulated in the
IFN condition. None of the 11 factors in our HLA−peptide
complex display list were downregulated upon IFN treatment,
while six were upregulated (P = 0.09). In agreement with our
initial hypothesis, IFN treatment upregulated factors directly
involved in HLA−peptide complex display. Contrary to naive
expectations, HBV transfection also tended to upregulate such
factors, although a host-derived IFN response could be causative
here. The expectation that HBV transfection would down-
regulate upstream components involved in positive regulation of
HLA−peptide complex display, that is, E3 ligases and their
accessories, was also met. The converse expectation, that IFN
would upregulate these components, was not met.
Examining the literature, several downregulated E3 ligases/
accessories under the HBV-transfection condition in this study
stand out. TRIM25 has been described as “essential” for RIG-I-
mediated antiviral activity49 and has previously been shown to
exhibit anti-HBV effects.50 These anti-HBV effects were
augmented by IFN-I treatment; TRIM25 was indeed upregu-
lated on IFN treatment in our own study. Although not
previously implicated in HBV inhibition, TRIM56 is also known
to be repressed by a wide variety of viruses, undoubtedly due to
its critical role in TLR3 antiviral signaling.51 CUL1 is also
targeted by numerous viruses, and its interaction with c-Myc has
been shown to be disrupted by the HBV HBx protein.52 Other
downregulated E3 ligases and accessories implicated in antiviral
processes (though not specifically HBV) include ATRX,53
HLTF,54 HUWE1,55 and RBBP6.56
While IFN-induced upregulation of E3 ligases and accessories
as a group did not reach significance, it is worth noting the
presence of several specific proteins that were significantly
altered under IFN stimulation (Figure 6, E3 table). Under IFN-I
and IFN-III conditions, DTX3L was strongly upregulated with
high significance [10-fold (P = 10−7) and 5-fold (10−6),
respectively]. The protein/transcript has shown to be
upregulated under IFN-stimulation or viral infection.57
DTX3L ubiquitinates a subset of histones, altering the
chromatin landscape to allow enhanced expression of
interferon-stimulated genes; other functions and/or ubiquityla-
tion targets have not, to our knowledge, been described. The
effect on histones was not described as degradative, and our own
work did not show significant downregulation of any histones.
Several ligases/accessories were upregulated upon IFN
stimulation without, to the best of our knowledge, previous
mention in the interferon literature: SCAF11, ANKFY1,
RNF149, and CUL4B. Of particular interest, both RNF149
and CUL4B ubiquitylate key components of the cell cycle
(BRAF and various histones, respectively) relevant to
cancer.58,59
We have suggested that HBV transfection triggers an IFN
response. It is not surprising, then, that proteins upregulated in
HepG2.2.15 versus HepG2 intersect significantly with those
upregulated in HepG2 upon IFN-I (P = 10−7) or IFN-III (P =
10−8) treatment. What would be interesting, however, are cases
where HBV-transfection apparently manipulates expression in a
direction opposite to that seen on IFN treatment. This indeed
occurred at significant levels; proteins significantly upregulated
in the HepG2.2.15/HepG2 comparison intersected with
proteins significantly downregulated on IFN-I treatment at P
= 10−7 and on IFN-III treatment at P = 10−3 (case A), while
proteins downregulated in the HepG2.2.15/HepG2 comparison
intersected with those upregulated on IFN-I/III treatment at P =
10−3 and 10−5 (case B). Using the GSEA enrichment tool,60 case
A proteins were enriched for involvement in oxidative
phosphorylation (P = 10−4) and numerous metabolic groups
(e.g. GO cofactor metabolic process, P = 10−3). We note two
studies in which HBV infection was accompanied by broad
upregulation of proteins and transcripts61 or metabolites62
relevant to glycolysis, the Krebs cycle, gluconeogenesis, lipid
metabolism, and energy production. Case B proteins were
enriched for poly-A RNA-binding (P = 10−5) and pyrimidine
metabolism (P = 10−3).
Analysis of Metabolic Protein Expression Changes.
Given the aforementioned evidence of alterations in proteins
associated with metabolism, we sought to identify metabolic
functions or regions of metabolism associated with significant
changes in protein expression. Our approach utilized a type of
gene set analysis (GSA) whereby gene sets are defined based on
the association of genes with other components of the metabolic
network, namely metabolites and subsystems (metabolic
pathways). This use of metabolites as gene sets is known as
“reporter metabolite analysis.”63
The reporter metabolite analysis revealed a few metabolites
associated with a significant enrichment in coordinated protein
expression increases or decreases (Figure 7a). The results
suggested increased activity in metabolic pathways involving
long-chain acyl-CoAs (e.g., linoleoyl-CoA and palmitoyl-CoA)
upon HBV transfection, attributed in part to an increased
expression of ELOVL1, ACAD, and ACSL proteins involved in
lipid biosynthesis and turnover (Figure S2A). These findings are
consistent with the previous studies showing an effect of HBV
infection on fatty acid metabolism.64 In particular, Yang et al.65
measured increased levels of palmitoleic acid in the livers of
HBV transgenic mice compared to those of wild-type, in
addition to observing amarked increase in the expression of lipid
metabolic proteins (FABP5 and ACBP).
The enrichment of decreased protein expression associated
with NADH and ubiquinol (and their oxidized counterparts)
observed upon IFN treatment of HepG2 cells reflects the similar
decrease observed in proteins associated with oxidative
phosphorylation observed in the subsystem GSA (Figure 7b)
and in the GSEA enrichment analysis described above. The
subsystem GSA also revealed an enrichment of protein
expression decreases upon IFN treatment in several other
pathways, such as amino acid metabolism, nucleotide metabo-
lism, and the TCA cycle (Figure 7b); however, no such
decreases were enriched upon treatment of HBV-transfected
HepG2 cells with IFN. The IFN-induced decrease of oxidative
phosphorylation and TCA cycle enzyme expression have been
reported previously; for example, Liu and colleagues observed a
decreased expression of genes associated with the TCA cycle
and glutamine catabolism upon treatment of macrophages with
IFN-L and LPS,66 and Lewis et al. reported a decreased
expression of mitochondrial gene expression and an electron
transport chain function in IFN-treated murine fibroblasts and
human lymphoblastoid cells.67 However, this effect appears to
be a function of cell type, as others have measured an increase in
oxygen consumption and oxidative phosphorylation activity in
mouse dendritic cells, keratinocytes, and memory T cells upon
IFN treatment.68
We next investigated metabolites and subsystems that were
associated with significant protein expression changes but
ignoring the direction of the change (increase or decrease).
Many more metabolites were found to be significantly enriched
in differential protein expression when the fold-change direction
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was excluded but only in the comparison of HBV-transfected
versus nontransfected HepG2 cells (Figure 7c). The majority of
the significant metabolites was acyl-CoAs, as observed in the
directional GSA results, but some metabolites were associated
with amino acid metabolism (glutamate, glutamine, glycine, and
alanine) and the TCA cycle (α-ketoglutarate). These findings
are supported by differences in metabolite exchange rates
between HepG2.2.15 and HepG2 cells measured by Li et al.,61
where significant metabolites included glutamate, alanine, and
α-ketoglutarate.
Although both IFN treatments and HBV transfection caused
significant expression changes in proteins involved in the TCA
cycle, the IFN treatment was associated with a coordinated
expression decrease, whereas HBV transfection was associated
with a mixture of expression decreases and increases (Figure
S2). The increased expression of some TCA cycle enzymes (e.g.,
CS, SDHB, and MDH2) upon HBV transfection observed here
is consistent with protein measurements reported by Li et al. in
their comparison of HepG2.2.15 with HepG2 cells.61 In
addition to the TCA cycle, proteins involved in processes such
as bile acid synthesis, purine metabolism, and glycolysis/
gluconeogenesis exhibited significant expression changes upon
HBV transfection, but such enrichment was not observed among
the IFN treatment conditions (Figure 7d).
Relevance to HBV-Associated Hepatocarcinoma
Treatment. A recent multiomics study examined HBV-
associated hepatocarcinoma (HCC) against adjacent tissue
from 159 patients at high depth at the proteomic level.69 As both
Gao’s work and our own involve high-depth proteomics, liver
cancer, and HBV infection/transfection, we took this oppor-
tunity to cross datasets in search of a potential insight that could
point to treatment strategies. Beginning with the 3749 proteins
in common in Gao’s work, our HBV transfection work and our
IFN work, we used Fisher’s exact test to examine all
combinations of our own results with Gao’s (e.g. upregulated
in HCC vs downregulated on IFN treatment). Interestingly, the
only strongly significant effect occurred when proteins down-
regulated by HBV-transfection were intersected with proteins
upregulated in cancer (P < 5 × 10−7) (Figure 8); proteins
upregulated in cancer tended to be downregulated in HBV-
transfected cells. The underlying data and intersecting sets are
shown in Table S2. It would appear, then, that HBV-transfection
induces a cellular state that is in opposition to that found in
HBV-related HCC, a surprising result given HBV’s well-
documented propensity for inducing HCC. Interpreting this
result is difficult. Interestingly, in Gao’s work HBV, protein
levels were significantly (P < 10−12 in the case of core protein)
higher in nontumorous tissue than tumorous tissue. Viral RNA
levels also tended to be higher in the nontumorous tissue (P <
10−3 for envelope and X transcripts). Thus, assuming that cancer
effects dominate viral effects in HBV-related HCC, two
hypotheses may be proffered: (1) cancer upregulates antiviral
Figure 8. Relevance of IFN treatment and HBV transfection to HCC. Venn diagram showing the intersection of proteins significantly downregulated
in our own IFN stimulation and HBV transfection work against Gao’s results showing proteins significantly upregulated in HBV-related HCC. Bar
graphs show enriched gene sets found at the intersections of our two studies and the HCC study.
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proteins which are downregulated by HBV (i.e. cells trans-
formed by HBV are hostile to further HBV replication) and (2)
HBV downregulates procancer proteins upregulated in cancer.
Examining proteins that are both upregulated by HCC and
downregulated by HBV showed strong enrichment for factors
involved in the cell cycle and DNA replication (Figure 8). While
these factors are not typically considered “antiviral”, it is
plausible that an environment of rapid cell division is not optimal
for HBV fitness. While this view is undoubtedly simplistic and
fails to address themechanisms by whichHBV initiates cancer, it
does complicate any picture in which the cell cycle deregulation
seen in both chronic HBV and advanced HCC are considered to
be well-aligned.70
While HBV transfection appeared more potent than IFN in
counteracting HCC’s proteomic effects, an HBV-based HCC
therapy is rationally dismissed as ridiculous. However, 14
proteins upregulated in HCC were downregulated by both IFN
andHBV-transfection (Figure 8), most of which play roles in the
cell cycle. We note the presence of two minichromosome
maintenance (MCM) proteins in this set, MCM4 and MCM7.
Further, of the seven MCM complex proteins common in all
three datasets (HCC, HBV-transfection, and IFN), six were
downregulated in the HBV-transfection condition. Targeting of
MCM complex proteins has indeed shown promise in
combatting liver cancer,71 prostate cancer,72 and breast
cancer.73 Other proteins within the 14 member set also figure
prominently in cancer research. ANXA2 is repeatedly
mentioned in the literature as promoting cancer invasive-
ness.74,75 ATOX1 has also been shown to play roles in cancer
migration.76 Inhibitors of TXNRD1 have also been developed
with the aim of sensitizing lung cancer cells to AKT
suppression.77 Scanning GEO datasets,8 we note a number of
studies in which drug treatments significantly reduced transcript
levels of multiple proteins in the 14 member set (Table S3).
These drugs vary widely in their mechanisms of action; erlotinib,
for example, is a tyrosine kinase inhibitor, trichostatin A targets
histone deacetylases, and pomalidomide has antiangiogenesis
activity. Of note is the fact that two of the drugs are easily
available at “health food” stores; octanoate (caprylic acid,
derived from coconut oil) and melatonin. Further studies are
required to examine the effects of these drugs at the protein level
in liver cancer cells for development of potential treatments.
The HBV HBx protein is widely thought to be largely
responsible for HBV-associated cell cycle alterations and for
HBV-associated carcinogenicity.78 On HBx overexpression,
expression of two proteins, NASP and ANXA2, found in our
14 member group has been shown to actually increase.79
However, these proteins were sharply downregulated in
HepG2.2.15 cells, with P < 10−7 in both cases. Such
discrepancies may indicate the HBV stage of infection that is
predominant in HepG2.2.15 cells, with HBV proteins found
near the limits of MS detection,12 as well as the extreme levels of
the HBx protein present in an overexpression context. In fact,
contradictory pro- and antiapoptotic functions have been noted
with respect to HBx,80 with speculation that such behavior
relates to HBx abundance in infected cells.81
■ CONCLUSIONS
Given the depth of our underlying IFN-stimulation proteomic
data, we hope that this data would be of use in interferon
research in the years to come. The inclusion of equally deep
HBV-transfection proteomic data allows for speculation into the
means by whichHBV, and possibly other viruses, may stymie the
interferon response. We were legitimately surprised to note the
relative absence of proteomic work on a perturbation that has
been extensively characterized at the transcriptomic level. This
observation, in turn, suggests that a number of proteomic studies
on otherwise well-characterized perturbations (knockdowns/
outs, overexpression, and drugs) await. Our own work points to
some of the “low hanging fruit” that could be targeted; proteins
that are directly involved in protein degradation or stabilization
(e.g. proteasome components and E3 ligases) and, as a
consequence, mediate the immunoprocessing effects of the
interferon.
■ MATERIALS AND METHODS
Cell Culture and IFN-Treatment. HepG2 cells were
cultured in DMEM (Gibco, MA), FBS (Gibco), 1% MEM-
NEAA (Gibco), and 1% penicillin/streptomycin (Gibco).
HepG2.2.15 cells, a gift from Professor Antonio Bertoletti
(Singapore Institute for Clinical Sciences, A*STAR), were
cultured as mentioned above, with the addition of Geneticin at
150 μg/mL. Cells were maintained at 37 °C, 5% CO2, in a
humidified incubator. In IFN-treatment versus control experi-
ments, 5 × 106 cells were seeded into T-75 flasks well plates and
grown for 24 h. Type I IFN in the form of IFN-α2a (11100-1,
PBL Assay Science, NJ) and type III IFN in the form of IFN-λ3
(5259-IL-025, R&D Systems, MN) were added to final
concentrations of 100 ng/mL, as previously optimized in ref 12.
Proteomics. In each experimental condition (IFN-stim-
ulation or HBV-transfection), five biological replicates were
performed. Cells were lysed using 5% sodium deoxycholate with
the addition of 1X protease inhibitor (Thermo), incubation for 3
min, and sonication. Cell debris was eliminated via centrifuga-
tion. Protein concentrations of all samples were determined
using the BCA protein assay (Thermo). All samples were
reduced with dithiothreitol (DTT) at 37 °C for 30min, followed
by alkylation with iodoacetamide at room temperature for 30
min in the dark. A quenching step was conducted with further
DTT treatment for 15 min, followed by overnight trypsin
treatment at 37 °C. 5% trifluoroacetic acid treatment, and
centrifugation was utilized to remove precipitates. Tryptic
peptide amounts were determined using the Pierce Quantitative
Fluorometric Peptide Assay (Thermo).
Dimethyl labeling of tryptic peptides followed, as previously
described, with a 1 h incubation period. Ammonia followed by
formic acid treatment was used to stop the reaction. All samples
used for downstream experiments were labeled at greater than
99% efficiency. Samples were combined and dried (SpeedVac)
at room temperature. To enhance identification of low-
abundance peptides, the pooled peptides were fractionated
into 10 fractions using the Pierce high pH reversed-phase
peptide fractionation kit (Thermo). All fractions were again
dried prior to LC−MS/MS analysis.
Samples were suspended in 0.1% FA to a volume of 15 μL. An
EASY-nLC1000 system (Thermo) coupled to a Q-Exactive
Orbitrap Plus mass spectrometer (Thermo) with a nano-
electrospray ion source was used for MS analysis.
Elution proceeded in 5−40% acetonitrile (ACN), 0.1% FA for
70 min, and 40−95% ACN, 0.1% FA, for 20 min with a 300 nL/
min flow rate. A full MS scan at resolution 70,000 was followed
by 10 data-dependent MS2 scans at resolution 17,500. The
normalized collision energy of HCD fragmentation was 32%.
The MS scan range was set to 350 to 1400 m/z. Precursors ions
with unassigned charge states, states of +1 or greater than +8,
were excluded. Dynamic exclusion of 30 s was set. Proteome
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Discoverer software 2.1 (Thermo) was used to generate peak
lists, and the SEQUEST-HT engine was used for data
processing. Databases used in search included a list of common
contaminants (www.thegpm.org/crap), the human UniProt
database (November 2018), and the hepatitis B virus UniProt
database (November 2018). Search parameters were set for
trypsin digestion, a maximum of 2 missed cleavages, up to 4
modifications, variable oxidation of methionine, and fixed
modifications: carbamidomethylation of cysteine (+57.02146
Da), as well as light, medium, and heavy dimethylation of N
termini and lysine (+28.031300, +32.056407, and +36.075670
Da). Mass tolerance for precursor ions was set to 10 ppm; and
mass tolerance for fragment ions was set at 0.02 Da. Known
contaminant ions were excluded. False discovery rate was based
on Q-values, set to 1%. Differential ratios between various
conditions were calculated by comparison of mean intensities;
when fewer than three ratios could be calculated, the proteins in
question were dropped from further analysis. An unpaired t-test
was used to calculate the significance of differential results.
The precursor ions quantifier node in Proteome Discoverer
software was employed to quantify the relative MS signal
intensities of dimethyl labeled peptides. The vehicle channel was
used as a denominator to generate abundance ratios of the IFN-
λ3/vehicle and IFN-α2/vehicle. The HepG2 channel was used
as a denominator to generate abundance ratios of HepG2.2.15/
HepG2. Log 2 of the normalized ratio was used to calculate the
mean and standard deviation of fold change across all five
biological replicates. When these ratios were found in less than
three experiments, the relevant proteins were excluded.
The MS data have been deposited to the ProteomeXchange
Consortium via the PRIDE82 partner repository with the dataset
identifier PXD017251.
Statistical Methods. Differential Analysis. In cases where
we speak of protein “upregulation” or “downregulation”,
significance at P < 0.05 (Student’s t-test) must be met. With
respect to proteins identified via dimethyl labeling, the proteins
were required to be identified in at least 3 of 5 reps in order to be
considered for differential analysis. For volcano plots, the R
package “plot” was used. In the heatmap, to whittle the list of
proteins down to about 200 strongly altered proteins for the
purpose of stringent clustering, we applied a filter to include only
proteins that exhibited substantial differential changes (ratios)
between experimental conditions. Specifically, we added a
requirement for entry; of the five log 2 ratios associated with a
given protein’s differential expression changes under different
experimental conditions, the smallest ratio subtracted from the
largest ratio must be greater than two. For heatmaps, the R
package “heatmap.2” was used to construct the heatmap in
Figure 5.
In the case of a list of canonical IFN-upregulated and
downregulated transcripts that we constructed, a transcript must
be upregulated in at least 6 of 18 studies or downregulated in 3 of
18, for inclusion (see Table S1 for the complete list of studies).
When using DAVID for enrichment analysis, a background of
6003 confidently identified proteins was set. In cases where an
option for input of “custom” backgrounds is not available (e.g.
GSEA), we downloaded the underlying sets that showed
apparent enrichment and then performed Fisher’s exact test
using the R-programming function “fisher.test”.
When calculating binomial probabilities, probabilities of
success were adjusted according to the total number of
significantly up- and downregulated proteins in a study. For
example, roughly 3 proteins were downregulated for every 2
upregulated under the HBV-transfection condition, meaning
that a downregulated protein has an a priori 60% chance of
success versus an upregulated protein.
Bioinformatics. PCA and Pearson Analysis. PCA was
performed via the R function “prcomp” (tidyverse library) and
plotted using the “fviz_pca_ind” function (factoextra). Any
columns containing non-numerical data were removed. For
Pearson analysis (R function “ggscatter” with the cor.method
parameter set to “pearson”), removal of non-numerical data was
not required, and the differential effects of IFN-I and IFN-III
were combined.
Metabolite Analysis. Metabolite and subsystem gene set
collections were extracted from the human genome-scale
metabolic model, Human-GEM.83 GSAs were performed
using the Piano package in R,84 which enables the incorporation
of fold-change directionality information when evaluating the
significance of gene set enrichment. A GSA was run for each of
the five conditions: transfection of HepG2 with HBV, treatment
of HepG2 with IFN-α2, treatment of HepG2 with IFN-λ3,
treatment of HBV-transfected HepG2 with IFN-α2, and
treatment of HBV-transfected HepG2 with IFN-λ3. All P-values
reported for the metabolite and subsystem GSA were corrected
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